Low-dose lithium aspartate did not improve fatigue and cognitive dysfunction symptoms in long COVID. A small dose-finding study suggested higher doses might be effective, but a new trial is needed.

BUFFALO, N.Y. — A small University at Buffalo clinical trial has found that at low doses, lithium aspartate is ineffective in treating the fatigue and brain fog that is often a persistent feature of ...

It asked how effective long-term therapy with low doses of lithium might be in slowing the decline of memory and cognitive function in individuals diagnosed with mild cognitive impairment, which is ...

Add Yahoo as a preferred source to see more of our stories on Google. A small dose of the nutritional supplement lithium asparate may not ease the fatigue and brain fog of Long COVID, but a larger ...

A small University at Buffalo clinical trial has found that at low doses, lithium aspartate is ineffective in treating the fatigue and brain fog that is often a persistent feature of long COVID; ...

A study published in Nature on August 6, 2025, found that lithium is the only metal significantly depleted in the prefrontal cortex of people with mild cognitive impairment and Alzheimer’s disease, ...

About The Study: This pilot randomized clinical trial established feasibility, confirmed safety and tolerability, and generated effect size estimates for future trials of low-dose lithium in mild ...

A once-daily dose of a medication, which averaged 195 mg, produced blood levels significantly lower than those typically pursued by psychiatrists. However, it succeeded in generating a weak signal ...